AA
MYGN icon

ALPS Advisors’s Myriad Genetics MYGN Stock Holding History

ALPS Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-13,780
Closed -$469K – 732
2014
Q4 		$469K Sell
13,780
-1,839
-12% -$65.3K ﹤0.01% 498
2014
Q3 		$602K Sell
15,619
-990
-6% -$36.9K ﹤0.01% 265
2014
Q2 		$646K Buy
16,609
+424
+3% +$15.8K 0.01% 287
2014
Q1 		$553K Sell
16,185
-2,721
-14% -$84.3K 0.01% 494
2013
Q4 		$522K Buy
18,906
+9,170
+94% +$232K 0.01% 327
2013
Q3 		$229K Buy
+9,736
New +$277K ﹤0.01% 590

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ALPS Advisors's MYGN Position: Q1 2015 in Review

ALPS Advisors sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 13,780 shares — an estimated $469K sold.

ALPS Advisors first reported a position in MYGN in Q3 2013 and held it in 6 quarters. The position peaked at $646K in Q2 2014. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

  • ALPS Advisors reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
  • ALPS Advisors sold 13,780 Myriad Genetics shares in Q1 2015, an estimated $469K.
  • ALPS Advisors first reported a position in Myriad Genetics in Q3 2013 and held it in 6 quarters.
  • ALPS Advisors's Myriad Genetics position peaked at $646K in Q2 2014.
  • 251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on ALPS Advisors's 13F filing for Q1 2015, filed 15 May 2015.